Mihael Hristos Polymeropoulos Buys 10,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was bought at an average price of $5.02 per share, with a total value of $50,200.00. Following the completion of the purchase, the chief executive officer now owns 2,285,731 shares of the company’s stock, valued at approximately $11,474,369.62. This represents a 0.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Friday, February 28th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The stock was bought at an average cost of $4.76 per share, with a total value of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock. The shares were purchased at an average price of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Price Performance

Shares of VNDA opened at $4.91 on Friday. The company’s 50-day moving average is $4.60 and its 200-day moving average is $4.79. The firm has a market capitalization of $286.33 million, a PE ratio of -15.34 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.71 and a fifty-two week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million for the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. Analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Verition Fund Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 2,927 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Vanda Pharmaceuticals by 17.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 3,370 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock worth $2,796,000 after buying an additional 3,473 shares during the last quarter. Franklin Resources Inc. grew its position in Vanda Pharmaceuticals by 8.8% during the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 4,449 shares during the last quarter. Finally, ProShare Advisors LLC increased its stake in shares of Vanda Pharmaceuticals by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 4,599 shares during the period. Institutional investors own 88.14% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright boosted their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.